The US Food and Drug Administration has cleared for marketing a non-invasive test that uses molecular expression techniques to assist doctors in managing heart transplant patients post-surgery for potential organ rejection.
Truman Medical Centers (TMC) became one of the first hospitals in the United States to install the Siemens SOMATOM Definition AS 128 slice CT scanner this week. The 128-slice CT scanner is a highly adaptive scanner, providing exceptional image quality with minimal radiation exposure to the patient.
Peakdale Molecular has launched AssayReady4U(TM) an online based storefront which allows drug discovery researchers the ability to search, design and select compounds from a live physical collection of screening compounds in collaboration with ChemPrintCo LLC .
Novartis AG stopped development of its Aurograb treatment for bacterial infections after it showed a lack of efficacy in mid-stage trials, and said it would take a $235 million impairment charge.
Dr Reddy's Laboratories Ltd has received approval from the U.S. Food and Drug Administration for trandolapril tablets, the regulator's website showed.
CMS, Inc., an Elekta Company and worldwide leader in radiation treatment planning and workflow management solutions, announced that three sites have delivered clinical treatments utilizing Monaco(TM), its next-generation Intensity Modulated Radiotherapy (IMRT) treatment planning system.
Israel-based Teva Pharmaceutical Industries has announced positive results of its Phase III Adagio trial.
Vitrolife has received approval from the Canadian authorities to start a study with STEEN Solution(TM). The study, which has been designed in consultation with the American FDA, is planned for quarters three to four of 2008 and will be the key element in the application for sales approval in USA and Canada.
Pfizer Limited has launched Toviaz®(Black Triangle Drug) (fesoterodine fumarate), a new once daily treatment for the symptoms of overactive bladder (OAB).
Edmonton's Research Park in Canada – new center, the first of its kind in Canada – will give entrepreneurs a place to turn ideas into viable, market-ready products.
Marksans Pharma, a Rs 240-crore plus Mumbai-based pharmaceutical company, has acquired RelonChem Ltd, one of UK's leading generic drug company for an undisclosed sum. RelonChem has clocked sales of US$ 32 million with adjusted EBITDA of US $5 million in 2007.
Purimox (Amoxicillin Trihydrate) manufactured by DSM Anti-Infectives (DAI) at its Toansa India plant has received European Certificate of Suitability.
Cordis has received CE mark approval to market the Cypher Select plus Sirolimus-eluting coronary stent for the treatment of acute myocardial infarction, more commonly known as a heart attack.
New screening tests and effective vaccines from Merck & Co and GlaxoSmithKline make tackling cervical cancer in poor countries a real possibility for the first time, researchers.
Cell Genesys, Inc. today announced that it has terminated VITAL-2, the second of two Phase 3 clinical trials of GVAX immunotherapy for prostate cancer, which compares GVAX immunotherapy in combination with Taxotere® (docetaxel) to Taxotere plus prednisone in patients with advanced-stage prostate cancer.
Bristol-Myers Squibb Company and Pfizer Inc provided an update on the apixaban clinical development program. The companies announced that new Phase II data in acute coronary syndrome patients (ACS) will be presented at the upcoming meeting of the European Society of Cardiology (ESC).
Algeta ASA (OSE: ALGETA), the Norwegian cancer therapeutics company, today announced that the primary objective of its BC1-03 Phase II pain palliation study was met. The results support the Clinical Profile of This Novel Anti-Cancer Agent Under Development to Improve the Survival of Patients With Hormone Refractory Prostate Cancer (HRPC).
Sun Pharmaceutical Industries Ltd. (Sun Pharma) said following the favourable Tel-Aviv court ruling in a case against Taro Pharmaceutical Industries Ltd. (Taro), it will be able to complete a previously announced tender offer to buy the outstanding shares in Taro.
Novartis announced today that Gleevec® (imatinib mesylate) tablets* has been granted priority review status by the US Food and Drug Administration (FDA) as the first therapy to be reviewed for use after surgery in kit-positive gastrointestinal stromal tumors (GIST).
Stereotaxis, Inc. announced today that it has received regulatory clearance from the U.S. Food and Drug Administration for its magnetically tipped, PowerAssert(TM) radiofrequency (RF) guidewire to cross chronic total occlusions in the peripheral vasculature.